BACKGROUND When ovarian carcinoma is diagnosed in stage I, up to 90% of patients can be cured with surgery and currently available chemotherapy. At present, less than 25% of cases are diagnosed at this stage. To increase the fraction of ovarian cancers detected at an early stage, screening strategies have been devised that utilize a rising serum CA125 level to trigger the performance of transva...

Background: The purpose of the present study was to compare the serum levels of IL6 and CA125 in women with and without endometriosis. They were also compared in mild, moderate and severe cases. Methods: In this case-control study, CA125 and IL6 levels in 76 women with laparoscopic proven endometriosis were compared with 76 women without evidence of endometriosis. Sensitivity, specificity, p...

Ovarian cancer is the most lethal gynaecologic cancer affecting women. The most widely used biomarker for ovarian cancer, CA125, lacks sensitivity and specificity. Here, we explored differences in glycosylation of CA125 between serum from patients with ovarian cancer and healthy controls. We found differences between CA125 N-glycans from patient sera compared to controls. These include increase...

background: the purpose of the present study was to compare the serum levels of il6 and ca125 in women with and without endometriosis. they were also compared in mild, moderate and severe cases. methods: in this case-control study, ca125 and il6 levels in 76 women with laparoscopic proven endometriosis were compared with 76 women without evidence of endometriosis. sensitivity, specificity, posi...

Preventing peritoneal implantation of carcinoma cells could prolong ovarian cancer patient remission and survival. Peritoneal cells constitutively express mesothelin, a ligand for CA125 that is expressed by tumor cells. Thus blocking CA125/mesothelin-dependent cell attachment may prevent or delay peritoneal metastatic recurrence. We developed a high-throughput screening system for reagents able...

UNLABELLED The role of the tumor markers CA125 and CA72-4 has been evaluated in the diagnosis and management of ovarian cancer. Both markers were measured in 30 patients with proven epithelial ovarian cancer, 30 patients with benign pelvic masses and 30 normal women. CA125 and CA72-4 were measured using the luminometric immunoassay and immunoradiometric assay respectively. All patients with ova...

Carbohydrate antigens (CA) 125 and 199 have now been widely used in diagnosis in lung cancer. However, the role of metastasis and prognosis of these two markers remains controversial and needs further clarification. Here we retrospectively analyzed CA125 and CA199 in 430 lung cancer patients. All patients were categorized to three groups (negative, moderate and high) according to the increased ...

3A5 is a novel antibody that binds repeated epitopes within CA125, an ovarian tumor antigen that is shed into the circulation. Binding to shed antigen may limit the effectiveness of therapeutic antibodies because of unproductive immune complex (IC) formation and/or altered antibody distribution. To evaluate this possibility, we characterized the impact of shed CA125 on the in vivo distribution ...

EGFR is deregulated, in several types of cancer, by three mechanisms: (1) activating gene mutations; (2) overexpression the transmembrane form and (3) altered ligand expression. Selective inhibitors have been suggested as first-line therapy lung cancer patients harboring mutations, tumors pancreas certain histotypes ovarian tumors. Carbohydrate antigen 125(CA125) Human Epididymis 4 are being us...

CA125 as a biomarker of ovarian cancer is ineffective for the general population. The aim of this study was to evaluate multiplexed bead-based immunoassay of multiple ovarian cancer-associated biomarkers such as transthyretin and apolipoprotein A1, together with CA125, to improve the identification and evaluation of prognosis of ovarian cancer. We measured the serum levels of CA125, transthyret...